Evidence map›Paper›PMID 28930292›Full record

ReviewNature reviews. Gastroenterology & hepatology2017

Proton-pump inhibitors: understanding the complications and risks.

Peter Malfertheiner, Arne Kandulski, Marino Venerito

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Gastroenterology & hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 12 pooled it
21.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 12 syntheses or guidelines pooled it, 300 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023
    Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Article
  16. Ways to improve the negative impact of proton pump inhibitors on biopsy-based test accuracy for Helicobacter pylori detection.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Peter MalfertheinerDepartment of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University Hospital, Leipziger Strasse 44, 39120 Magdeburg, Germany.
Arne KandulskiDepartment of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University Hospital, Leipziger Strasse 44, 39120 Magdeburg, Germany.
Marino VeneritoDepartment of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University Hospital, Leipziger Strasse 44, 39120 Magdeburg, Germany.
Otto-von-Guericke University Magdeburg · DEUniversity Hospital Leipzig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proton-pump inhibitors (PPIs) are the most effective therapy for the full spectrum of gastric-acid-related diseases. However, in the past decade, a steadily increasing list of complications following long-term use of PPIs has been reported. Their potent acid-suppressive action induces several structural and functional changes within the gastric mucosa, including fundic gland polyps, enterochromaffin-like cell hyperplasia and hypergastrinaemia, which can be exaggerated in the presence of Helicobacter pylori infection. As discussed in this Review, most associations of PPIs with severe adverse events are not based on sufficient evidence because of confounding factors and a lack of plausible mechanisms. Thus, a causal relationship remains unproven in most associations, and further studies are needed. Awareness of PPI-associated risks should not lead to anxiety in patients but rather should induce the physician to consider the appropriate dosing and duration of PPI therapy, including long-term monitoring strategies in selected groups of patients because of their individual comorbidities and risk factors.

Indexed as

Drug Administration ScheduleDrug MonitoringEvidence-Based MedicineGastritisGastrointestinal MicrobiomeHelicobacter InfectionsHelicobacter pyloriHumansProton Pump InhibitorsRisk FactorsStomach DiseasesProton Pump Inhibitors

Identifiers

PMID28930292
OpenAlexW2758704163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.